Crispr Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Oppenheimer issued their Q2 2020 earnings per share (EPS) estimates for Crispr Therapeutics in a research note issued to investors on Tuesday, November 12th, Zacks Investment Research reports. Oppenheimer analyst S. Tuerkcan anticipates that the company will earn ($0.95) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $80.00 target price on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q3 2020 earnings at ($1.29) EPS and Q4 2020 earnings at ($1.38) EPS.

Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.

CRSP has been the subject of several other research reports. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Piper Jaffray Companies reiterated a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a research note on Tuesday. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research note on Tuesday, November 19th. Finally, Canaccord Genuity increased their price target on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $69.54.

CRSP stock opened at $71.65 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The company has a market capitalization of $3.80 billion, a price-to-earnings ratio of -20.83 and a beta of 3.15. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $74.00. The stock has a fifty day moving average of $49.98 and a 200-day moving average of $46.23.

Institutional investors and hedge funds have recently modified their holdings of the company. BSW Wealth Partners bought a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $39,000. Balyasny Asset Management LLC bought a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $5,165,000. BNP Paribas Arbitrage SA bought a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $41,000. Bank of New York Mellon Corp boosted its position in shares of Crispr Therapeutics by 116.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after acquiring an additional 17,810 shares during the last quarter. Finally, ARK Investment Management LLC boosted its position in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after acquiring an additional 701,332 shares during the last quarter. Hedge funds and other institutional investors own 49.81% of the company’s stock.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the transaction, the director now owns 7,500 shares in the company, valued at approximately $390,000. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by corporate insiders.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link